التفاصيل البيبلوغرافية
| العنوان: |
PILOT PHASE II STUDY OF SELINEXOR IN COMBINATION WITH IFOSFAMIDE, ETOPOSIDE AND DEXAMETHASONE IN PATIENTS WITH RELAPSED OR REFRACTORY PERIPHERAL T‐CELL LYMPHOMAS (R/R PTCLS). |
| المؤلفون: |
Chiappella, A., Dodero, A., Carniti, C., Miceli, R., Bermema, A., Ladisa, V., Zinzani, P. L., Corradini, P. |
| المصدر: |
Hematological Oncology; Jun2023 Supplement 1, Vol. 41, p845-846, 2p |
| مصطلحات موضوعية: |
IFOSFAMIDE, ETOPOSIDE, CUTANEOUS T-cell lymphoma, T cells, LYMPHOMAS, TUMOR suppressor genes, DEXAMETHASONE |
| مستخلص: |
B Introduction: b The prognosis of I R i / I R i PTCLs is very poor. All patients will receive intravenous S-IDE on a 21-day cycle: Selinexor (40 mg on day 3, 5 and 7); Ifosfamide 5 g/mq on day 2; Etoposide 100 mg/mq on days 1-3; Dexamethasone 20 mg/day on days 3-7. PILOT PHASE II STUDY OF SELINEXOR IN COMBINATION WITH IFOSFAMIDE, ETOPOSIDE AND DEXAMETHASONE IN PATIENTS WITH RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMAS (R/R PTCLS). [Extracted from the article] |
|
Copyright of Hematological Oncology is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
